GlassScriptPhysician profile
Nisarfathima Kazimuddin
NPI 1124028006
$3,509.86
in general payments reported to CMS, 2019-2025
45 companies · $896 in 2025
The $896 reported for 2025 was more than what 76% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $192 · 2021: $209 · 2022: $701 · 2023: $527 · 2024: $634 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761 · Consulting Fee: $150 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.17 |
| Consulting Fee | $150.00 |
| Education | $145.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $349.13 | 2019-2025 | Arikayce, Brinsupri |
| Harmony Biosciences LLC | $328.91 | 2024-2025 | |
| Jazz Pharmaceuticals INC. | $191.60 | 2019-2025 | |
| Inspire Medical Systems, INC. | $188.60 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.14 | 2020-2023 | |
| Mylan Specialty L.P. | $179.11 | 2019-2024 | Yupelri |
| Regeneron Healthcare Solutions, INC. | $178.56 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $173.33 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Merck Sharp & Dohme LLC | $160.12 | 2022-2025 | Zerbaxa, Recarbrio, Dificid |
| Actelion Pharmaceuticals US, INC. | $149.20 | 2022-2024 | Uptravi, Opsumit |
| Baxter Healthcare | $111.52 | 2022-2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Life 2000 Ventilation System, Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $99.61 | 2021-2023 | |
| Inari Medical, INC. | $89.27 | 2022 | |
| Genzyme Corporation | $87.88 | 2022-2024 | |
| La Jolla Pharmaceutical Company | $71.31 | 2024-2025 | Giapreza |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nisarfathima Kazimuddin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.